- Home
- CZNC vs VSTM Comparison
CZNC vs VSTM Comparison
Compare CZNC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | VSTM |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 303.2M |
| IPO Year | 2009 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CZNC | VSTM |
|---|---|---|
| Price | $23.78 | $4.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $23.50 | $16.50 |
| AVG Volume (30 Days) | 68.2K | ★ 2.8M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 17.49 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $3.11 | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | $1,181.50 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $18.16 | $3.43 |
| 52 Week High | $24.25 | $11.25 |
Technical Indicators
Market Signals| Indicator | CZNC | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 66.48 | 57.79 |
| Support Level | $23.07 | $4.00 |
| Resistance Level | $23.96 | $6.67 |
| Average True Range (ATR) | 0.61 | 0.33 |
| MACD | 0.23 | 0.08 |
| Stochastic Oscillator | 80.56 | 92.98 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.